Skip to main content

Foghorn Therapeutics Inc.

FHTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001822462

No open-market purchases or sales by Foghorn Therapeutics Inc. insiders were filed in the last 90 days; 102 institutions reported holding it in 13F filings for Q2 2026, worth $219.2M in total; no superinvestor holds it.

Q3 2021 vs. Q2 2021

How the institutions holding Foghorn Therapeutics Inc. changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of FHTX: Q2 2021 compared with Q3 2021
MeasureQ2 2021Q3 2021Change
Holders3947+8
Shares23.9M24.3M+371.9K (+1.6%)
Value$255.1M$338.2M+$83.1M (+32.6%)

New holders (11)

Institutions that held Foghorn Therapeutics Inc. at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to FHTX in Q3 2021
InstitutionSharesValue% of portfolio
Kingdon Capital Management, L.L.C.205,741$2.87M0.50%
Pura Vida Investments, LLC68,095$949.0K0.07%
J. Goldman & Co LP67,500$940.0K0.08%
Goldman Sachs Group Inc12,809$178.0K0.00%
SG Americas Securities, LLC10,925$152.0K0.00%
MetLife Investment Management8,683$121.0K0.00%
Metropolitan Life Insurance Co6,569$91.5K0.00%
Advisor Group Holdings, Inc.750$10.0K0.00%
US Bancorp73$1.00K0.00%
Quadrant Capital Group LLC89$1.00K0.00%
Ellevest, Inc.4$00.00%

Sold out (3)

Institutions that held Foghorn Therapeutics Inc. at the end of Q2 2021 and filed for Q3 2021 without it.

Institutions that sold out of FHTX in Q3 2021
InstitutionShares, Q2 2021Value, Q2 2021
NewSquare Capital LLC5,000$53.0K
Signaturefd, LLC76$1.00K
Wells Fargo & Company38$0